Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2008. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share option grants rather than a financial performance report.
Material Changes
The material change reported is the grant of share options to six individuals under the GlaxoSmithKline UK Savings Related Share Option Plan on October 23, 2008. The details are as follows:
- Option Price: £9.51 per share
- Grant Date: October 23, 2008
- Recipients and Quantity:
- Mr S M Bicknell: 1,009 shares
- Mr E J Gray: 1,009 shares
- Mr A S Hussain: 1,009 shares
- Mr D Learmouth: 1,009 shares
- Mr D S Redfern: 1,009 shares
- Mr A Witty: 1,009 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director transactions.
Investor Verification Points
- Verify the total number of shares granted (6,054) against the company's total outstanding share count to assess dilution impact.
- Confirm the exercise price of £9.51 relative to the market price of GSK shares on October 23, 2008.
- Review the specific vesting terms and conditions of the UK Savings Related Share Option Plan not detailed in this summary.